These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 33330842)

  • 21. An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine.
    Dragojevic Simic V; Miljkovic M; Stamenkovic D; Vekic B; Ratkovic N; Simic R; Rancic N
    Int J Clin Pract; 2021 Mar; 75(3):e13825. PubMed ID: 33156564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).
    Shah S; Das S; Jain A; Misra DP; Negi VS
    Int J Rheum Dis; 2020 May; 23(5):613-619. PubMed ID: 32281213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
    Choudhury M; Dhanabalan AK; Goswami N
    J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia.
    Purwati ; Miatmoko A; Nasronudin ; Hendrianto E; Karsari D; Dinaryanti A; Ertanti N; Ihsan IS; Purnama DS; Asmarawati TP; Marfiani E; Yulistiani ; Rosyid AN; Wulaningrum PA; Setiawan HW; Siswanto I; Tri Puspaningsih NN
    PLoS One; 2021; 16(6):e0252302. PubMed ID: 34143818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity.
    Tsuji M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.
    Martins-Filho PR; Ferreira LC; Heimfarth L; Araújo AAS; Quintans-Júnior LJ
    Lancet Reg Health Am; 2021 Oct; 2():100062. PubMed ID: 34485970
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19: A simulation study.
    Okada JI; Yoshinaga T; Washio T; Sawada K; Sugiura S; Hisada T
    Clin Transl Sci; 2021 May; 14(3):1092-1100. PubMed ID: 33404133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19: Potential Repurposing Drugs.
    Leowattana W
    Infect Disord Drug Targets; 2022; 22(1):e110122191924. PubMed ID: 33645490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro.
    Ni Y; Liao J; Qian Z; Wu C; Zhang X; Zhang J; Xie Y; Jiang S
    Bioorg Med Chem; 2022 Jan; 53():116523. PubMed ID: 34875467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
    Barratt-Due A; Olsen IC; Nezvalova-Henriksen K; Kåsine T; Lund-Johansen F; Hoel H; Holten AR; Tveita A; Mathiessen A; Haugli M; Eiken R; Kildal AB; Berg Å; Johannessen A; Heggelund L; Dahl TB; Skåra KH; Mielnik P; Le LAK; Thoresen L; Ernst G; Hoff DAL; Skudal H; Kittang BR; Olsen RB; Tholin B; Ystrøm CM; Skei NV; Tran T; Dudman S; Andersen JT; Hannula R; Dalgard O; Finbråten AK; Tonby K; Blomberg B; Aballi S; Fladeby C; Steffensen A; Müller F; Dyrhol-Riise AM; Trøseid M; Aukrust P;
    Ann Intern Med; 2021 Sep; 174(9):1261-1269. PubMed ID: 34251903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.
    Kumar J; Jain S; Meena J; Yadav A
    J Infect Chemother; 2021 Jun; 27(6):882-889. PubMed ID: 33678548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
    Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
    Negru PA; Radu AF; Vesa CM; Behl T; Abdel-Daim MM; Nechifor AC; Endres L; Stoicescu M; Pasca B; Tit DM; Bungau SG
    Biomed Pharmacother; 2022 Mar; 147():112700. PubMed ID: 35131656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RETRACTED ARTICLE: Discovery of (
    Rabie AM
    Chem Zvesti; 2021; 75(9):4669-4685. PubMed ID: 34025012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Silico Identification of New Anti-SARS-CoV-2 Main Protease (M
    Onyango H; Odhiambo P; Angwenyi D; Okoth P
    J Trop Med; 2022; 2022():3697498. PubMed ID: 36263438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells.
    Sacramento CQ; Fintelman-Rodrigues N; Dias SSG; Temerozo JR; Da Silva APD; da Silva CS; Blanco C; Ferreira AC; Mattos M; Soares VC; Pereira-Dutra F; Miranda MD; Barreto-Vieira DF; da Silva MAN; Santos SS; Torres M; Chaves OA; Rajoli RKR; Paccanaro A; Owen A; Bou-Habib DC; Bozza PT; Souza TML
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
    Drożdżal S; Rosik J; Lechowicz K; Machaj F; Kotfis K; Ghavami S; Łos MJ
    Drug Resist Updat; 2020 Dec; 53():100719. PubMed ID: 32717568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.
    Deshpande RR; Tiwari AP; Nyayanit N; Modak M
    Eur J Pharmacol; 2020 Nov; 886():173430. PubMed ID: 32758569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
    Mallhi TH; Ahmad A; Butt MH; Misbah S; Khan YH; Alotaibi NH
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):124-128. PubMed ID: 33115586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.